Selecta Biosciences Inc (1S7.SG)
| Previous Close | 13.24 |
| Open | 0.44 |
| Bid | 0.46 x 0 |
| Ask | 0.47 x 0 |
| Day's Range | 0.44 - 13.24 |
| 52 Week Range | 0.44 - 17.79 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireCartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GAITHERSBURG, Md., April 04, 2024--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:00 p.m. ET.
Business WireCartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., April 04, 2024--Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2024, the Company issued to each of these employees an option to purchase shares of the Company’s common stock with an exercise price of $0.5601, the closing trading price of the Company’s common stock on th
GlobeNewswireCartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
Proposals approved at Company’s special meeting of stockholders held March 27, 2024GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced results from a special meeting of stockholders held March 27, 2024. During the meeting, Cartesian stockholders approved the issuance of shares of common stock upon conversion of Cartesian’s Ser
